In an adolescent currently taking fluvoxamine 75 mg at bedtime, should the dose be increased to 100 mg as a single nightly dose or divided into multiple doses?

Fluvoxamine Dosing: Single vs. Divided Dose at 100 mg

You can continue the single bedtime dose when increasing from 75 mg to 100 mg in this adolescent—divided dosing is not required until the total daily dose exceeds 50 mg in children or adolescents. 1

FDA-Approved Dosing Guidelines

The FDA label for fluvoxamine provides clear guidance on when divided dosing becomes necessary in pediatric populations 1:

• Starting dose for adolescents (ages 8-17): 25 mg once daily at bedtime
• Dose increases: 25 mg increments every 4-7 days as tolerated
• Critical threshold: Total daily doses greater than 50 mg should be given in two divided doses
• When doses are unequal: Give the larger dose at bedtime
• Maximum dose for adolescents: Up to 300 mg/day (adult maximum)

Your Specific Clinical Scenario

Since your patient is currently on 75 mg at bedtime and you're increasing to 100 mg:

• Both 75 mg and 100 mg exceed the 50 mg threshold
• Technically, divided dosing is recommended per FDA labeling 1
• However, you have flexibility in implementation

Practical Approach

Option 1 (Most conservative, aligns with FDA label):

• Split to 50 mg in morning + 50 mg at bedtime when moving to 100 mg total
• This follows the letter of the FDA guidance 1

Option 2 (Pragmatic, if tolerability is good):

• Continue 100 mg as single bedtime dose
• Monitor closely for tolerability over first 24-48 hours 2
• Consider splitting if adverse effects emerge

Rationale for Flexibility

The AACAP guidelines emphasize that fluvoxamine is a shorter-acting SSRI requiring careful dose titration at 1-2 week intervals 2. The recommendation for divided dosing stems from:

1. Pharmacokinetic considerations: Fluvoxamine has a mean half-life of 15.6 hours in adolescents 1, which is relatively short
2. Tolerability: Divided dosing may reduce peak-related side effects like nausea, anxiety, or agitation 2
3. Non-linear pharmacokinetics: Higher doses produce disproportionately higher concentrations 1

Key Monitoring Points

Regardless of your dosing choice, monitor closely for 2:

• First 24-48 hours after dose change: Critical window for adverse effects
• Behavioral activation/agitation: Initial adverse effect of SSRIs can be anxiety or agitation 2
• Suicidal ideation: Black box warning requires close monitoring, especially after dose adjustments 3
• GI symptoms: Nausea, diarrhea, abdominal discomfort 2
• Sleep disturbances: Insomnia or vivid dreams 2

Common Pitfall to Avoid

Do not assume once-daily dosing is always adequate just because the patient tolerates 75 mg at bedtime. The non-linear pharmacokinetics of fluvoxamine mean that a 25 mg increase can produce disproportionately higher plasma concentrations 1. If adverse effects emerge at 100 mg once daily, immediately consider splitting the dose rather than reducing the total daily dose, as this maintains therapeutic benefit while improving tolerability.

Gender Consideration

If your patient is female, be particularly attentive to tolerability. Female children and adolescents show higher plasma concentrations and may achieve therapeutic benefit at lower doses 1, 4, though this effect is most pronounced in younger children (ages 6-11) rather than adolescents.